Delving into the Latest Updates on Ropeginterferon alfa-2b-NJFT with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

mono-pegylated interferon - PharmaEssentia Corporation, Peg-IFN-alpha-2b, PEG-P-IFN-alpha-2b

+ [14]

Target

IFNAR

Action

agonists, stimulants, inducers

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesOther Diseases+ [2]

Active Indication

Polycythemia VeraPrimary MyelofibrosisThrombocythemia, Essential+ [2]

Inactive Indication

Chronic hepatitis C genotype 2Chronic phase chronic myeloid leukemiaHepatitis B Virus-Related Hepatocellular Carcinoma+ [2]

Originator Organization

PharmaEssentia Corp.

Active Organization

PharmaEssentia Corp.

PYRAMID Laboratories, Inc.PharmaEssentia Japan KK

+ [4]

Inactive Organization-

License Organization

FORUSTherapeutics, Inc.

Aop Orphan Pharmaceuticals GmbHPint Pharma GmbH

+ [1]

Drug Highest PhaseApproved

First Approval Date

European Union (15 Feb 2019),

Polycythemia Vera

RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Sequence Code 533526748

Source: *****

This is a randomized, open-label, multicenter, two-arm study to assess the efficacy and safety of ropeginterferon alfa-2b for patients with PV. The entire study period is 60 weeks, including a main treatment phase (32 weeks), an extension treatment phase (24 weeks), and a safety follow-up phase (four weeks). However, the study may be extended for additional period of treatment after Week 60 pending the primary endpoint analysis at Week 32. Approximately 70 patients with PV will be enrolled.

Start Date01 Jan 2025

Sponsor / Collaborator

PharmaEssentia Corp.

NCT06468033

/ Not yet recruitingPhase 3

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b (P1101) in Adult Patients With Pre-fibrotic/Early Primary Myelofibrosis (PMF) or Overt PMF at Low or Intermediate-1 Risk According to DIPSS Plus

This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk.
Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.

Start Date01 Dec 2024

Sponsor / Collaborator

PharmaEssentia Corp.

100 Clinical Results associated with Ropeginterferon alfa-2b-NJFT

Login to view more data

100 Translational Medicine associated with Ropeginterferon alfa-2b-NJFT

Login to view more data

100 Patents (Medical) associated with Ropeginterferon alfa-2b-NJFT

Login to view more data

254

Literatures (Medical) associated with Ropeginterferon alfa-2b-NJFT

01 Jun 2025·Pharmacology Research & Perspectives

Population Pharmacokinetics‐Pharmacodynamics and Exposure‐Response of Ropeginterferon Alfa‐2b in Chinese and Japanese Patients With Polycythemia Vera

Article

Author: Wu, Lei ; Suo, Shanshan ; Shen, Weihong ; Komatsu, Norio ; Sato, Toshiaki ; Shimoda, Kazuya ; Li, Yaning ; Liao, Jason ; Chen, Haoqi ; Su, Xia ; Zhang, Lei ; Fu, Rongfeng ; Wu, Daoxiang ; Jin, Jie ; Kirito, Keita ; Gao, Yucheng ; Qin, Albert ; Wang, Wei ; Zhang, Jingjing

ABSTRACT:

Ropeginterferon alfa‐2b (ropeg) represents a new‐generation interferon‐based therapy approved for polycythaemia vera (PV) treatment. This study aimed to elucidate its population pharmacokinetics‐pharmacodynamics (PopPK‐PD) and exposure‐response (E‐R) relationships. A PopPK model was developed using pooled data from four clinical studies, including two Phase I studies in healthy volunteers (n = 48) and two Phase II studies in Chinese or Japanese patients with PV (n = 78). Sequential modeling was used to analyze pharmacokinetics‐pharmacodynamics (PK‐PD) regarding hematological parameters, including hematocrit, platelet, and white blood cell counts. Hematological changes were simulated using fast‐ and slow‐dose titration regimens. Individual exposure values were used to analyze the E‐R relationships regarding complete hematologic response (CHR), driver mutation, JAK2V617F allele burden, and safety. In this study, we developed a target‐mediated drug disposition model. Sigmoid indirect effects elucidated the PK‐PD in terms of hematological changes. Simulations showed that the fast‐titration regimen significantly accelerated hematocrit reduction. Logistic regression models showed that the probability of achieving CHR increased with exposure at Week 24 but not at Week 52. In contrast, JAK2V617F allele reductions correlated with exposure at both Weeks 24 and 52. Exposure‐safety analysis revealed a manageable risk of adverse events associated with transaminase increases. This study established a robust framework for ropeg PK‐PD, providing insights into its E‐R relationships and disease‐modifying action.Trial Registration: A17‐102, A19‐201, and A20‐202 are registered at ClinicalTrials.gov. The registration numbers are as follows: A17‐102, NCT03546465; A19‐201, NCT04182100; and A20‐202, NCT05485948. A17‐101 is registered at www.chinadrugtrials.org.cn. The registration number is CTR20190451

01 May 2025·HemaSphere

Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)

Letter

Author: Illes, Arpad ; Empson, Victoria ; Krochmalczyk, Dorota ; Dulicek, Petr ; Egyed, Miklos ; Hasselbalch, Hans C. ; Gercheva‐Kyuchukova, Liana ; Sivcheva, Lylia ; Kiladjian, Jean‐Jacques ; Gisslinger, Heinz ; Kralovics, Robert ; Klade, Christoph ; Georgiev, Pencho ; Pylypenko, Halyna ; Krejcy, Kurt ; Mayer, Jiří ; Yablokova, Vera

01 May 2025·Therapeutic Advances in Hematology

Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa—case report, review of the literature and multidisciplinary clinical practice recommendations

Article

Author: Zeerleder, Sacha S. ; Odermatt, Urs ; de Gottardi, Andrea ; Brand, Christoph ; Fischli, Stefan ; Melzer, Ralph ; Wuillemin, Walter A. ; Rüfer, Axel

Pegylated interferons alfa are increasingly used in patients with myeloproliferative neoplasms (MPN) due to their potential disease-modifying effect. Ropeginterferon alfa-2b has been approved for patients with polycythemia vera (PV) with no symptomatic splenomegaly as first-line cytoreductive therapy, based on the results of the PROUD-PV/CONTINUATION-PV studies, documenting significantly higher rates of complete hematologic response (CHR) compared with hydroxyurea from 2-year timepoint onward. Although safety profile of pegylated interferons is overall good, interferon-related toxicities can occur. Focus of this article is on interferon-mediated autoimmune diseases. We describe two patients with PV treated with pegylated interferons alfa, one patient developed a cutaneous, paranasal sarcoidosis without any systemic symptoms and was successfully treated with topical steroids. The other patient developed widespread psoriatric skin lesions, which were treated with moderate effect with topical therapy with calcipotriene and betamethasone dipropionate foam, antidry calm lotion and in the course of the disease with ultraviolet light therapy (UVB). Only with methotrexate she achieved a nearly complete remission of the psoriasis. In both patients pegylated interferon was continued in view of the CHR and therefore the beneficial effect on MPN. We review the pertinent literature on the management of interferon-mediated autoimmune diseases in patients with MPN. As there is little published evidence on that topic, we propose multidisciplinary clinical practice recommendations based on available evidence and clinical experience in the management of patients with MPN treated with pegylated interferon alfa.

47

News (Medical) associated with Ropeginterferon alfa-2b-NJFT

20 Mar 2025

·www.businesswire.com

Pint Pharma Announces ANVISA’s Approval of BESREMi® (ropeginterferon alfa-2b) for the Treatment of Polycythemia Vera

SÃO PAULO--(BUSINESS WIRE)--Pint Pharma and PharmaEssentia announced today that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow. This results in a persistent increase in red blood cells, white blood cells, and platelets. PV can lead to cardiovascular complications such as thrombosis and embolism, and in a significant number of patients it can progress to secondary myelofibrosis or leukemia. The global incidence of PV is estimated at approximately 2.8 cases per 100,000 people per year. In Brazil, between 2016 and 2020, DataSUS recorded 1,843 cases of Polycythemia Vera, representing an incidence of 0.16 per 100,000 inhabitants. Despite being a rare disease, these numbers suggest the possibility of underdiagnosis and underreporting, highlighting a challenge in identifying affected patients. According to Fernanda Bertasi, General Manager of Pint Pharma in Brazil, "ANVISA’s approval of BESREMi® represents a transformative milestone for patients with Polycythemia Vera in Brazil. This new therapeutic option brings real hope, offering innovation and progress in disease treatment. This is an essential step in providing better health and well-being for these patients." Valnei Canutti, Hematologist and Chief Scientific Officer at Pint Pharma, emphasized that "BESREMi® is an innovative, monopegylated interferon with extended action due to its unique pharmacokinetic properties. Its approval was based on robust evidence from the PEGINVERA clinical study, which demonstrated superior and more sustained hematologic and clinical responses compared to standard therapy." For David Ricardo Muñoz Guzmán, CEO of Pint Pharma, "This therapeutic advancement reaffirms Pint Pharma’s commitment to being a community-centered company. Our mission goes beyond innovation and high technology, focusing on solutions that truly impact patients' lives by expanding access to treatments and improving healthcare quality." Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia, added, "The approval of BESREMi® by ANVISA is a testament to the power of strong cross-border partnerships in advancing healthcare and reinforces our mission to transform care for PV patients worldwide. We deeply appreciate the collaboration with the Pint Pharma team, whose expertise and dedication have been instrumental in bringing BESREMi® to patients in Brazil." BESREMi® is exclusively registered, marketed, and distributed by Pint Pharma in Brazil. About BESREMi® (ropeginterferon alfa-2b) in Polycythemia Vera (PV) BESREMi® is an innovative, monopegylated, long-acting interferon that has marketing authorization in over 40 countries, with approval from the European Medicines Agency (EMA) in 2019, the U.S. Food and Drug Administration (FDA) in 2021, and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan in 2023.. With its exclusive pegylation technology, BESREMi® offers extended activity in the body and is designed for administration once every two weeks (or once every four weeks if hematologic stability is maintained for at least 1.5 years), allowing for flexible dosing tailored to individual patient needs. About PharmaEssentia PharmaEssentia Corporation (TWSE: 6446) headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. About Pint Pharma Pint Pharma is a biopharmaceutical company that specialises in the commercialisation of innovative therapies with the potential to transform outcomes in rare disease and other patient communities across the Latin American region. By collaborating with world-class biotech and pharma companies, Pint Pharma is committed to improving the lives of Latin American patients in areas of significant unmet medical need. The company is headquartered in Europe and counts with over 250 employees across its territories in Latin America including Brazil, Mexico, Argentina, Colombia, Chile, Peru and Ecuador. Pint Pharma licensed from PharmaEssentia the rights to commercialize BESREMi® in Brazil.

Drug Approval

20 Mar 2025

·www.pharmaindustrial-india.com

Pint Pharma Gets ANVISA Approval of BESREMi for Polycythemia Vera

Pint Pharma and PharmaEssentia have announced that ANVISA (Brazilian Health Regulatory Agency) has approved BESREMi® (ropeginterferon alfa-2b) for the treatment of adult patients with Polycythemia Vera (PV). Polycythemia Vera (PV) is a rare, chronic, debilitating, and potentially fatal myeloproliferative neoplasm, originating from a disease-initiating stem cell in the bone marrow. This results in a persistent increase in red blood cells, white blood cells, and platelets. PV can lead to cardiovascular complications such as thrombosis and embolism, and in a significant number of patients it can progress to secondary myelofibrosis or leukemia. The global incidence of PV is estimated at approximately 2.8 cases per 100,000 people per year. In Brazil, between 2016 and 2020, DataSUS recorded 1,843 cases of Polycythemia Vera, representing an incidence of 0.16 per 100,000 inhabitants. Despite being a rare disease, these numbers suggest the possibility of underdiagnosis and underreporting, highlighting a challenge in identifying affected patients. According to Fernanda Bertasi, General Manager of Pint Pharma in Brazil, "ANVISA’s approval of BESREMi® represents a transformative milestone for patients with Polycythemia Vera in Brazil. This new therapeutic option brings real hope, offering innovation and progress in disease treatment. This is an essential step in providing better health and well-being for these patients." Valnei Canutti, Hematologist and Chief Scientific Officer at Pint Pharma, emphasized, "BESREMi® is an innovative, monopegylated interferon with extended action due to its unique pharmacokinetic properties. Its approval was based on robust evidence from the PEGINVERA clinical study, which demonstrated superior and more sustained hematologic and clinical responses compared to standard therapy." David Ricardo Muñoz Guzmán, CEO of Pint Pharma said, "This therapeutic advancement reaffirms Pint Pharma’s commitment to being a community-centered company. Our mission goes beyond innovation and high technology, focusing on solutions that truly impact patients' lives by expanding access to treatments and improving healthcare quality." Ko-Chung Lin, Ph.D., Founder and CEO of PharmaEssentia, added, "The approval of BESREMi® by ANVISA is a testament to the power of strong cross-border partnerships in advancing healthcare and reinforces our mission to transform care for PV patients worldwide. We deeply appreciate the collaboration with the Pint Pharma team, whose expertise and dedication have been instrumental in bringing BESREMi® to patients in Brazil."

Drug Approval

17 Feb 2025

·www.aop-health.com

AOP Health: ICC Arbitral Tribunal rules in favor of AOP Health in arbitration proceedings pertaining to BESREMi® (Ropeginterferon alfa-2b)

(Vienna, 17.02.2025) Today, a tribunal under the auspices of the International Chamber of Commerce (ICC) served a partial final award in a dispute between PharmaEssentia Corp. (“PharmaEssentia”) and AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in AOP Health’s favor. At the heart of the case were reciprocal claims for damages arising from a dispute regarding a licensing agreement between the parties. The product in dispute The conflict centers around ropeginterferon alfa-2b, a substance launched in 2019 and that AOP Health has developed into an innovative treatment (BESREMi®) for rare blood cancers, particularly polycythemia vera, through a comprehensive clinical trial program. This makes BESREMi® the best investigated interferon in clinical trials in this indication as documented in the major relevant guidelines1. AOP Health had acquired the rights for both BESREMi®’s development and commercialization in the European, Commonwealth of Independent States (CIS), and Middle Eastern markets from PharmaEssentia in 2009. In its sixth year after its approval by European Medicines Agency (“EMA”), AOP Health has successfully made BESREMi® available to an estimated 9,000 patients in AOP Health’s licensed territory. First arbitration and set-aside proceedings Since 2017, PharmaEssentia repeatedly sought to terminate its agreement with AOP Health regarding BESREMi®. In October 2020, an ICC Arbitral Tribunal ruled these attempts unjustified. AOP Health was awarded approx. EUR 143 million in damages for project delays caused by PharmaEssentia, while the latter´s counterclaims were dismissed. PharmaEssentia’s 2021 application to set aside the award was rejected by the Frankfurt Higher Regional Court. Upon its subsequent appeal to the German Federal Supreme Court, the agreement’s validity and the dismissal of PharmaEssentia 's counterclaims was upheld. The German Federal Supreme Court found procedural flaws with respect to damage quantification of the awarded approx. EUR 143 million, impacting the damages awarded. Second arbitration In November 2020, PharmaEssentia initiated a legal action against AOP Health, alleging damage claims. AOP Health in turn claimed damages for delays in BESREMi®’s European approval caused by PharmaEssentia, and the misuse of AOP Health’s clinical trial data for PharmaEssentia’s US marketing authorization. Result: partial final award in favor of AOP Health While the partial final award rules in favor of AOP Health regarding PEC's intentional breaches and liability for several claims, the tribunal’s decision on the quantum of those claims is yet to be made. AOP Health welcomes this decision. It will continue to supply patients in need of ropeginterferon alfa-2b (BESREMi®). 1 ELN Guideline (2022), NCCN Guideline (2024), Onkopedia Leitlinie (2023) Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: About BESREMi® BESREMi® is the first interferon that was approved for polycythemia vera, a myeloproliferative neoplasm (MPN), indicated in the European Union as monotherapy in adults for treatment of polycythemia vera without symptomatic enlarged spleen. Its overall safety and efficacy were demonstrated in multiple clinical studies. BESREMi® (ropeginterferon alfa-2b) is a long-acting, mono-pegylated proline interferon (ATC L03AB15). It is administered once every 2 weeks initially, or up to every 4 weeks after stabilization of blood values. BESREMi® is designed to be self-administered subcutaneously with a pre-filled pen. For the EMA Summary of Product Characteristics please visit: BESREMi® AOP Health is a global healthcare group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. At the end of 2024, AOP Health received its first U.S. FDA approval for RapiblykTM, a medication aimed at patients in intensive care units, thereby further strengthening its commitment to making therapies available for patients worldwide. The AOP Health Group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the AOP Health Group’s actions. Mag. Nina Roth, MAS Head of Corporate Communications nina.roth[at]aop-health.com photocredit stock-photo: shutterstock_2012352206

Drug ApprovalPatent InfringementLicense out/in

100 Deals associated with Ropeginterferon alfa-2b-NJFT

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11027	Ropeginterferon alfa-2b-NJFT	L03AB15	DB15119

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Polycythemia Vera	European Union	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Iceland	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Liechtenstein	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019
Polycythemia Vera	Norway	Aop Orphan Pharmaceuticals GmbH	15 Feb 2019

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Myelofibrosis	Phase 3	-	PharmaEssentia Corp.	01 Dec 2024
Thrombocythemia, Essential	Phase 3	United States	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	China	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Japan	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Canada	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Hong Kong	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Singapore	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	South Korea	PharmaEssentia Corp.	25 Aug 2020
Thrombocythemia, Essential	Phase 3	Taiwan Province	PharmaEssentia Corp.	25 Aug 2020
Chronic phase chronic myeloid leukemia	Phase 3	France	Aop Orphan Pharmaceuticals GmbH	04 May 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04285086 (EXCEED-ET, Biospace) Manual	Phase 3	Thrombocythemia, Essential Second line	174	P1101 (Ropeginterferon alfa-2b-njft)	zkqggtezau(wclqhycbna) = jpfmxouire ejjqjdbqgy (ljtmmbsnnp ) Met View more	Positive	06 Jan 2025
NCT04285086 (EXCEED-ET, Biospace) Manual	Phase 3	Thrombocythemia, Essential Second line	174	Anagrelide	zkqggtezau(wclqhycbna) = dyotgbkecs ejjqjdbqgy (ljtmmbsnnp ) Met View more	Positive	06 Jan 2025
EHA2024 Manual	Phase 2	Polycythemia Vera JAK2V617F VAF \| IFNL4	114	Ropeginterferon alfa-2b (Ropeg)	evgeavdfzm(ncqefusszz) = hpxjmhnnzw qcmgeqfevs (qoqfkpgfpa )	Positive	14 May 2024
EHA2024 Manual	Phase 2	Polycythemia Vera JAK2V617F VAF \| IFNL4	114	Ropeginterferon alfa-2b (Ropeg)py, STD)	evgeavdfzm(ncqefusszz) = ygatvsbozj qcmgeqfevs (qoqfkpgfpa )	Positive	14 May 2024
EUCTR2012-005259-18-CZ \| EUCTR2014-001357-17-PL (PROUD-PV, EHA2024) Manual	Phase 3	Polycythemia Vera JAK2V617F allele burden	169	ropeginterferon alfa-2b	yvhuadybjg(vzxcvydike) = ziumjjrifj nximewvvrc (azysfuztdu ) View more	Positive	14 May 2024
	Phase 3	Polycythemia Vera JAK2V617F allele burden	169	HU/BAT	yvhuadybjg(vzxcvydike) = ppcewtcooe nximewvvrc (azysfuztdu ) View more	Positive	14 May 2024
EHA2024	Phase 2	Polycythemia Vera JAK2 V617F allele burden	27	Ropeginterferon alfa-2b	bnogspxkte(zqzxotbzat) = Although most patients (25/27 [92.6%]) experienced adverse events (AEs), ropeginterferon alfa-2b was generally well tolerated. The most common AEs were WBC count decreased (7/27 [25.9%]) and urine beta-2 microglobulin increased (6/27 [22.2%]) pmyjnoykhb (zxfawycbaa ) View more	Positive	14 May 2024
EHA2024	Phase 3	Polycythemia Vera	34	Ropeginterferon alfa-2b	oufpniwgcc(kuofvdutyy) = One patient developed autoimmune thyroiditis without the need to suspend treatment uaymhubtfp (tsapqqmcqm ) View more	Positive	14 May 2024
PROUD-PV/CONTINUATION (EHA2024)	Phase 3	Second line JAK2 mutated	12	Ropeginterferon alfa-2b	bwtjgxfcxz(spitqbrcrp) = One withdrew therapy due to intolerance (flushing and eczema, grade 1) after 9 months of treatment dwnjjvsowc (upsgtszzdk )	Positive	14 May 2024
PROUD-PV/CONTINUATION-PV (ASH2023)	Not Applicable	Polycythemia Vera	-	Ropeginterferon alfa-2b	gdwqbbmhfz(wlyzjicbzr) = acnntskqqo cqarisviac (waxgtnioth )	-	11 Dec 2023
ASH2023	Not Applicable	Polycythemia Vera	99	P1101	awvbvgvpvv(hiibonsxdw) = uxfzfgddzq qtiuggzsyo (yqrrgffast ) View more	-	11 Dec 2023
P1101MF (ASH2023)	Phase 2	Primary Myelofibrosis	-	Ropeginterferon alfa 2b	nlncwvjipv(ggfcekomtl) = iimtlaxffc bzqbbmofjm (gsxxexqxnc ) View more	-	11 Dec 2023
CTR20211664 \| NCT05485948 (Pubmed 1 \| Pubmed 2 \| Exp Hematol Oncol) Manual	Phase 2	Polycythemia Vera	49	ropeginterferon alfa-2b	afxeqkggix(zzeekghgpz) = sledjahhza nwtxulqsnu (xmpwkuomoz ) View more	Positive	21 Jun 2023

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.